A director at Evotec SE bought 20,000 shares at 5.475EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Q3/25-KPIs zeigen eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -11% YoY auf € 164 Mio./Marge: -9,17 %; EPS € -0,24), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Die anhaltend schwache Nachfrage im Markt für frühe Arzneimittelforschung (D&PD) konnte das gut gelaufene Geschäft von Just-Evotec Biologics (JEB) nur teilweise ausgleichen. Zudem kämpft Evotec mit Unterauslastung. Hinzu kommen Kosten im Zusammenhang mit dem Anlaufen der JEB-Anlage im französisch...
Q3/25 KPIs show a decline in revenue and EBITDA margins (revenue -11% YoY to €164m / margin: -9.17%; EPS € -0.24), but these are exaggerated due to phasing effects and reset savings. The persistently weak demand in the early drug discovery (D&PD) market could only partially offset the well-performing business of Just-Evotec Biologics (JEB). Additionally, Evotec is struggling with underutilization. There are also costs associated with the start-up of the JEB facility in Toulouse, France, which is...
Two Directors at Next sold 52,518 shares at between 14,044p and 14,520p. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.